Matus Hajduk, on behalf of MindMed. At MindMed we use rigorous science to develop our industry-leading, evidence-based pipeline of product candidates that have the potential to transform the treatment landscape for brain health disorders.
We strive to deliver on the therapeutic potential of psychedelics and other novel compounds to address unmet patient needs in Generalized Anxiety Dosorder, Major Depressive Dosorder and Autism Spectrum Disorder.
